enGene enters $100M at-the-market equity facility with Leerink Partners

enGene Therapeutics Inc.

New Sales Agreement with Leerink Partners for up to $100M in common shares via at-the-market offerings.
Prior Open Market Sale Agreement with Jefferies LLC terminated on March 6, 2026; no shares sold and no penalties.
Leerink will receive a commission of up to 3.0% of gross proceeds; Company may reimburse certain expenses.
Shares will be sold under Rule 415(a)(4); Company not obligated to sell any shares.
No shares offered or sold in Canada under the new agreement.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

enGene Therapeutics Inc. entered into Sales Agreement with Leerink Partners LLC valued at up to $100,000,000 (effective 2026-03-09).

Action: entry
Agreement: atm program
Counterparty: Leerink Partners LLC
Value: up to $100,000,000
Effective: 2026-03-09

Exact text from the filing

On March 9, 2026, enGene Holdings Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with Leerink Partners LLC (“Leerink Partners”), pursuant to which the Company may sell its common shares, without par value (the “Common Shares”), from time to time through Leerink Partners.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

enGene Therapeutics Inc. terminated Open Market Sale Agreement with Jefferies LLC valued at terminated Prior Sales Agreement; no shares sold (effective 2026-02-27).

Action: termination
Agreement: atm program
Counterparty: Jefferies LLC
Value: terminated Prior Sales Agreement; no shares sold
Effective: 2026-02-27

Exact text from the filing

On February 27, 2026, the Company delivered written notice to Jefferies LLC that effective as of March 6, 2026, the Company terminated the Open Market Sale Agreement SM , dated as of December 20, 2024 (the “Prior Sales Agreement”), that the Company had previously entered into with Jefferies LLC, as sales agent.

View on SEC.gov

300 material agreements filed in the last 30 days. Browse all material agreements →

enGene Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-097546

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.